Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: A report from the children’s oncology group

Douglas S. Hawkins, Yueh Yun Chi, James R. Anderson, Jing Tian, Carola A.S. Arndt, Lisa Bomgaars, Sarah S. Donaldson, Andrea Hayes-Jordan, Leo Mascarenhas, Mary Beth Mccarville, Jeannine S. Mccune, Geoff Mccowage, Lynn Million, Carol D. Morris, David M. Parham, David A. Rodeberg, Erin R. Rudzinski, Margarett Shnorhavorian, Sheri L. Spunt, Stephen X. SkapekLisa A. Teot, Suzanne Wolden, Torunn I. Yock, William H. Meyer

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Fingerprint Dive into the research topics of 'Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: A report from the children’s oncology group'. Together they form a unique fingerprint.

Medicine & Life Sciences